’Reasonable’ pricing could limit the cost for Zolgensma in France - STAT
▻https://www.statnews.com/2019/09/18/zolgensma-reasonable-pricing-france
In a March 31, 2018, submission to the U.S. Securities and Exchange Commission, AveXis included a highly redacted copy of the license from Généthon.
Redacted-contract
When I looked at the file, I noticed that the redactions were flawed, and that only the background color of the redacted parts had been changed. It was simple to load the document into a word processor, change the background colors, and create a completely unredacted version.